Figure 3
From: Targeting Mdmx to treat breast cancers with wild-type p53
KD of Mdmx impeded MCF-7 cells in a p53-dependent manner. MCF-7 cells expressing Mdmx shRNA or control shRNA (shMdmx wobble control) were treated and analyzed as described in Figure 2, with the exception that half the samples were also treated with the p53 inhibitor pifithrin-α (2.5 μM PFTα). For the analysis of cell numbers (a) and GFP positivity (b), cells were treated for 5 days. PFTα offered statistically significant protection against Mdmx shRNA, both for cell numbers (a, P=0.0027) and also for numbers of GFP positive cells (b, P=0.0018). For the measurement of Mdmx and p21 expression, cells were treated for 3 days and analyzed by RT-PCR (c). All the experiments represent triplicates. Errors bars represent S.D. of mean. P-values were calculated by Student’s t-test
